ALS drug development lukewarm despite icy hot challenge

The ALS Ice Bucket Challenge has brought awareness, money and even controversy to a rare disease that is both debilitating and fatal to the 5,600 people diagnosed per year, yet it hasn't poured new drug opportunities into the development pipeline.

The ALS Ice Bucket Challenge has brought awareness, money and even controversy to a rare disease that is both debilitating and fatal to the 5,600 people diagnosed per year, yet it hasn't poured new drug opportunities into the development pipeline.

According to the ALS Association, the Ice Bucket Challenge – which dares people to create a video of them pouring ice water on their heads or donate money to the nonprofit – has raised $88.5m so far in August. That's up from just $2.6m during the same month last year

More from Neurological

More from Therapy Areas

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By 

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.